Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha post-exposure prophylaxis for COVID-19 in cancer patients
ACTRN12620000842965Phase 3Withdrawn
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Interferon-alpha intranasal spray with Matching placebo intranasal spray (2 arms). Primary endpoints: Coprimary outcome 1 and Coprimary outcome 2. Planned start Sep 2020; status: withdrawn.
02
Drugs
interferon alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000842965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000842965.